Literature DB >> 16947082

The role of the epidermal growth factor receptor in breast cancer.

Samuel K Chan1, Mark E Hill, William J Gullick.   

Abstract

Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in breast cancer. The epidermal growth factor receptor or EGFR is a closely related receptor from this same family that is involved in cellular signal transduction and tumor cell growth and survival. Emerging evidence indicates that EGFR is implicated in the development of hormone-resistant breast cancer, and that its activity is intertwined with estrogen receptor. Here, the role of EGFR in breast cancer is reviewed, and data from selected clinical trials of signal transduction inhibition of this cellular target are summarized.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16947082     DOI： 10.1007/s10911-006-9008-2

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN： 1083-3021            Impact factor:   2.673


  62 in total

Review 1.  Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

Authors:  S K Chan; W J Gullick; M E Hill
Journal:  Eur J Cancer       Date:  2006-01       Impact factor: 9.162

2.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Authors:  Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

3.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

4.  Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.

Authors:  George Fountzilas; Dimitrios Pectasides; Anna Kalogera-Fountzila; Dimosthenis Skarlos; Haralambos P Kalofonos; Christos Papadimitriou; Dimitrios Bafaloukos; Stefanos Lambropoulos; Savvas Papadopoulos; Helen Kourea; Christos Markopoulos; Helen Linardou; Dimitrios Mavroudis; Evangelos Briasoulis; Nicholaos Pavlidis; Evangelia Razis; Paraskevas Kosmidis; Helen Gogas
Journal:  Breast Cancer Res Treat       Date:  2005-07       Impact factor: 4.872

5.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.

Authors:  Corinna Warburton; Wieslawa H Dragowska; Karen Gelmon; Stephen Chia; Hong Yan; Dana Masin; Tetyana Denyssevych; Anne E Wallis; Marcel B Bally
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

Review 7.  Erlotinib OSI/Roche/Genentech.

Authors:  Tracy E Kim; John R Murren
Journal:  Curr Opin Investig Drugs       Date:  2002-09

8.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 9.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

Authors:  J G Klijn; P M Berns; P I Schmitz; J A Foekens
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

10.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.

Authors:  Anne Camirand; Mahvash Zakikhani; Fiona Young; Michael Pollak
Journal:  Breast Cancer Res       Date:  2005-04-12       Impact factor: 6.466
View more
  31 in total

1.  3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.

Authors:  Massod Rahimi; Kai-Ling Huang; Careen K Tang
Journal:  Cancer Lett       Date:  2010-03-17       Impact factor: 8.679

2.  A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Authors:  S Thrane; A M Pedersen; M B H Thomsen; T Kirkegaard; B B Rasmussen; A K Duun-Henriksen; A V Lænkholm; M Bak; A E Lykkesfeldt; C W Yde
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

3.  Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis.

Authors:  Lin He; Xinhua Liu; Jianguo Yang; Wanjin Li; Shumeng Liu; Xujun Liu; Ziran Yang; Jie Ren; Yue Wang; Lin Shan; Chengjian Guan; Fei Pei; Liandi Lei; Yu Zhang; Xia Yi; Xiaohan Yang; Jing Liang; Rong Liu; Luyang Sun; Yongfeng Shang
Journal:  Cell Res       Date:  2018-08-22       Impact factor: 25.617

Review 4.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

5.  Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Authors:  Mothaffar F Rimawi; Priya B Shetty; Heidi L Weiss; Rachel Schiff; C Kent Osborne; Gary C Chamness; Richard M Elledge
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

6.  Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.

Authors:  Linette Castillo-Pichardo; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2012       Impact factor: 2.900

7.  Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

8.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

Review 9.  Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.

Authors:  Priscilla Merriam; William M Sikov
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-10-26

10.  Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer.

Authors:  Mads Thomassen; Qihua Tan; Torben A Kruse
Journal:  BMC Cancer       Date:  2008-12-30       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.